# FDA Grants Accelerated Approval to Zenbexus (iberdomide) for Relapsed or Refractory Multiple Myeloma

> fda · REPORTED · 2026-08-13

The FDA granted accelerated approval to Bristol-Myers Squibb's Zenbexus (iberdomide), a cereblon-modulating protein degrader, in combination with daratumumab, hyaluronidase-fihj, and dexamethasone for multiple myeloma. The application received Priority Review and iberdomide had previously received Breakthrough Therapy and Orphan Drug designations; the review was conducted under Project Orbis with Swissmedic.

About Bristol-Myers Squibb: Bristol-Myers Squibb is a global biopharmaceutical company with a broad oncology and hematology portfolio; Zenbexus is its novel protein-degrader therapy targeting multiple myeloma patients who have exhausted prior lines of therapy.

- Company: Bristol-Myers Squibb
- Sector: oncology
- Primary source: https://oncodaily.com/fda-approvals/fda-566069

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.